Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005997 · ClinicalTrials.gov registry record · Phase 2
Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary Cancer
A Phase 2 study, sponsored by Case Comprehensive Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT00005997 is a Phase 2 study that was terminated before completion, run by Case Comprehensive Cancer Center. The registered enrollment target is 72 participants.
The verdict
NCT00005997, a Phase 2 study, was terminated before completion, sponsored by Case Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analogue in treating patients who have advanced liver and/or biliary cancer.
Interventions
- DRUG becatecarin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 1999-04 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005997
The ClinicalTrials.gov registry entry for NCT00005997 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which becatecarin is the first listed.
NCT00005997 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005997 about?
NCT00005997 is a clinical study titled "Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analogue in treating patients who have advanced liver and/or biliary cancer.
What is the current status of trial NCT00005997?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 1999-04. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00005997?
The interventions under investigation include: becatecarin (DRUG).
Who is sponsoring clinical trial NCT00005997?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.